Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
  • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0043—Nose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the invention relates generally to rifabutin combination therapies for treating A. baumannii infections.
• MDR multi-drug resistant
• XDR extensively-drug resistant
• A. baumannii infections Treatment of A. baumannii infections is challenging.
• strains of A. baumannii have developed resistance to antibiotics in several different classes, including aminoglycosides, aminocyclitols, tetracyclines, chloramphenicol, and carbapenems.
• Polymyxins, such as colistin are typically used as a last resort due to their serious side effects, but so e A. baumannii strains are resistant to colistin as well (Zubair et al, 2015). Consequently, current tools for treating and preventing illness caused by this bacterium are inadequate for many patients.
• Rifampicin also known as rifampin
• Rifampicin has shown synergy with colistin towards A. baumannii , however, the result of this combination is dependent on the rifampin’s MICs (Giannouli et al , 2012).
• no synergistic effect of rifampicin and colistin was observed in A. baumannii isolates in which elevated rifampicin MICs were due to mutations in the rpoB target gene.
• the invention provides combination therapies that include rifabutin and a second antibiotic, such as a polymyxins (e.g. colistin, polymyxin B, polymyxin B nonapeptide; polymyxin analogues as exemplified by MRX-8, ) other cationic antimicrobial peptides (e.g. SPR741; chimeric peptidomimetic antibiotics exemplified by POL7306; octapeptin cyclic peptides) or cefiderocol, for treating A. baumannii infections.
• a polymyxins e.g. colistin, polymyxin B, polymyxin B nonapeptide; polymyxin analogues as exemplified by MRX-8,
• other cationic antimicrobial peptides e.g. SPR741; chimeric peptidomimetic antibiotics exemplified by POL7306; octapept
• the combinations of antibiotics display synergy to a wide range of A. baumannii strains.
• the synergy greatly increases the susceptibility of A. baumannii cells to rifabutin and colistin, with some strains displaying over a 500-fold increase in sensitivity to one of those antibiotics used in combination with the other compared to when that antibiotic is used by itself.
• combinations of rifabutin and colistin act synergistically to inhibit growth of strains that are resistant to both of those antibiotics when they are provided individually and therefore making those strains susceptible to the combination treatment even when the elevated MICs to rifabutin and rifampicin are due to mutations in the rpoB gene.
• the invention unlocks the therapeutic potential of antibiotics in settings in which they are otherwise impotent and provides effective therapies for treatment of serious A. baumannii infections.
• the invention provides methods of treating an A. baumannii infection in a subject by providing to a subject infected with A. baumannii rifabutin and a second antibiotic.
• the second antibiotic may be a polymyxin (e. g. colistin, polymyxin B, polymyxin B nonapeptide) or cefiderocol.
• the subject may be infected with strain of A. baumannii that is resistant to one or more antibiotics.
• the strain may be resistant to one or more of an aminocyclitol, aminoglycoside, beta-lactam, beta-lactamase inhibitor, carbapenem, cephalosporin, polymyxin, quinolone, rifamycin, sulfonamide, minocycline, eravacycline, sulbactam, and tetracycline.
• the strain may be resistant to one or more of amikacin, trimethoprim-sulfamethoxazole, cefepime, cefiderocol, ceftazidime, chloramphenicol, ciprofloxacin, colistin, polymyxin B, doripenem, gentamicin, imipenem, levofloxacin, meropenem, penicillin, piperacillin, rifabutin, rifampicin, tazobactam, and tigecycline.
• Each antibiotic may be administered by a separate route of administration. Two or more of the antibiotics may be administered by the same route of administration. Each antibiotic may independently be administered intravenously, orally, parenterally, subcutaneously, by inhalation, by injection, and/or by infusion.
• Each antibiotic may be administered in a separate formulation. Two or more of the antibiotics may be administered in a single formulation. The antibiotics may be administered according to the same dosing regimen, or two or more antibiotics may be administered according to different dosing regimens.
• the dosing regimen may include one or more of a dosage, dosage frequency, or interval between dosages.
• the subject may be a human.
• the subject may be a pediatric, a newborn, a neonate, an infant, a child, an adolescent, a pre-teen, a teenager, an adult, or an elderly subject.
• the subject may be in critical care, intensive care, neonatal intensive care, pediatric intensive care, coronary care, cardiothoracic care, surgical intensive care, medical intensive care, long-term intensive care, an operating room, an ambulance, a field hospital, or an out-of-hospital field setting.
• the method may include providing one or more antibiotics in addition to the first two antibiotics, e.g., rifabutin and either colistin or cefiderocol.
• the one or more additional antibiotics may be an aminocyclitol, aminoglycoside, beta-lactam, beta-lactamase inhibitor, carbapenem, cephalosporin, polymyxin, quinolone, rifamycin, sulfonamides, minocycline, eravacycline, sulbactam, and tetracycline.
• the one or more additional antibiotics may be amikacin, trimethoprim-sulfamethoxazole, cefepime, cefiderocol, ceftazidime, chloramphenicol, ciprofloxacin, colistin, doripenem, gentamicin, imipenem, levofloxacin, meropenem, penicillin, piperacillin, polymyxin B, rifabutin, rifampicin, tazobactam, and tigecycline.
• the invention provides combination therapies that include rifabutin and a second antibiotic in a therapeutically effective amount to treat an A. baumannii infection in a subject.
• the second antibiotic may be a polymyxin (e. g. colistin, polymyxin B, polymyxin B nonapeptide) or cefiderocol.
• the subject may be infected with strain of A. baumannii that is resistant to one or more antibiotics, such as any of those described above.
• Each antibiotic may be administered by a separate route of administration. Two or more of the antibiotics may be administered by the same route of administration. Each antibiotic may independently be administered intravenously, orally, parenterally, subcutaneously, by inhalation, by injection, and/or by infusion.
• Each antibiotic may be administered in a separate formulation. Two or more of the antibiotics may be administered in a single formulation. The antibiotics may be administered according to the same dosing regimen, or two or more antibiotics may be administered according to different dosing regimens.
• the dosing regimen may include one or more of a dosage, dosage frequency, or interval between dosages.
• the subject may be human or a class of humans, such as any of those described above.
• the combination therapy may include providing, in a therapeutically effective amount, one or more additional antibiotics, such as any of those described above.
• the invention provides uses of combinations the include rifabutin and a second antibiotic for making one or more medicaments for treating an A. baumannii infection in a subject.
• the second antibiotic may be colistin or cefiderocol.
• the subject may be infected with strain of A. baumannii that is resistant to one or more antibiotics, such as any of those described above.
• each antibiotic is administered by a separate route of administration. In embodiments of the use, two or more of the antibiotics are administered by the same route of administration. In embodiments of the use, each antibiotic is independently be administered intravenously, orally, parenterally, subcutaneously, by inhalation, by injection, and/or by infusion. In embodiments of the use, each antibiotic is administered in a separate formulation. In embodiments of the use, two or more of the antibiotics are administered in a single formulation. In embodiments of the use, the antibiotics are administered according to the same dosing schedule. In embodiments of the use, two or more of the antibiotics are administered according to different dosing schedules. The dosing schedule may include one or more of a dosage, dosage frequency, or interval between dosages.
• the subject is a human or a member of a class of humans, such as any of those described above.
• the combination includes one or more additional antibiotics, such as any of those described above.
• FIG. 1 is an image of a 96-well plate checkerboard of A. baumannii cells cultured in various concentrations of rifabutin and colistin.
• FIG. 2 is an image of a 96-well plate checkerboard of A. baumannii cells cultured in various concentrations of rifabutin and cefiderocol.
• the invention provides combination therapies for treating an A. baumannii infection in a subject.
• the combination therapies are based on the finding that rifabutin acts synergistically with antibiotics such as colistin and cefiderocol to inhibit growth of A. baumannii cells. Therefore, the use of rifabutin in combination with either colistin or cefiderocol is more effective than use of any of those antibiotics alone in treating A. baumannii infections.
• the combination of rifabutin and colistin are even effective against ⁇ baumannii strains that are resistant to both of the antibiotics when given individually but become susceptible to treatment when given in combination.
• the combination therapies of the invention include two antibiotics that act synergistically to inhibit growth of A. baumannii cells.
• Synergy between antibiotics such as a rifabutin and colistin, may be determined by any suitable method.
• One method includes determining the minimum inhibitory concentration (MIC) for each antibiotic individually and in combination and calculating a Fractional Inhibitory Concentration Index (FICI) as follows:
• the pair of antibiotics is characterized as acting synergistically or not based on the FICI according to the following criteria: synergy (FICI ⁇ 0.5); indifferent (FICI >0.50 and ⁇ 4); antagonistic (FICI >4). Determining synergy of antibiotics based on the FICI is described in, for example, Jenkins, S. G. & Schuetz, A. N. Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy. Mayo Clin. Proc. 87, 290-308 (2012), the contents of which are incorporated herein by reference.
• the combination therapies of the invention one of the antibiotics is rifabutin.
• the combination therapies include a second antibiotic that act synergistically with the rifabutin.
• the second antibiotic may be a polymyxin, such as colistin, or a cephalosporin, such as cefiderocol.
• Colistin may be provided as colistimethate sodium or colistin sulfate.
• the combination therapies may include additional antibiotics, e.g., they may include 3, 4, 5, or more different antibiotics.
• Each antibiotic may independently be an aminocyclitol, aminoglycoside, beta-lactam, beta- lactamase inhibitor, carbapenem, cephalosporin, polymyxin, quinolone, rifamycin, sulfonamide, minocycline, eravacycline, sulbactam, or tetracycline.
• Each antibiotic may independently be amikacin, trimethoprim-sulfamethoxazole, cefepime, cefiderocol, ceftazidime, chloramphenicol, ciprofloxacin, colistin, doripenem, gentamicin, imipenem, levofloxacin, meropenem, penicillin, piperacillin, polymyxin B, rifabutin, rifampicin, tazobactam, or tigecycline.
• Rifabutin is a dark red-violet powder, has a molecular formula of C46H62NO11, a molecular weight of 847.02 and the following structure:
• Rifabutin has a broad spectrum of antimicrobial activity. It is considerably more active than rifampin against MAC, M. tuberculosis , and M leprae. It is also active against most atypical mycobacteria, including M kansasii ; M chelonae , however, is relatively resistant. Rifabutin is also active against staphylococci, group A streptococci, N gonorrhoeae , N meningitidis , H. injluenzae, H. ducreyi, C. jejuni, H. pylori, C. trachomatis, I gondii and A. baumannii.
• each antibiotic may be administered by any suitable route of administration.
• each antibiotic may independently be administered intravenously, orally, parenterally, subcutaneously, by inhalation, by injection, and/or by infusion.
• One or more antibiotics in the combination therapies may be administered to the same dosing regimen.
• One or more antibiotics may be administered according to different dosing regimens.
• a dosing regimen may include a dosage, a schedule or administration, or both.
• a dosage may be described by an absolute amount of drug (e.g. mg), or by a relative amount of the drug to the subject (e.g. mg/kg).
• a schedule of administration may be described by the interval between doses. For example and without limitation, the interval between doses may be about an hour, about 2 hours, about 3 hours, about 4 hours, about 6 hours, about 8 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, or more.
• One or more of the antibiotics may be provided in a single formulation.
• One or more antibiotics may be provided in separate formulations.
• Each formulation may be prepared for delivery by a particular route of administration, such as intravenously, orally, parenterally, subcutaneously, by inhalation, by injection, and/or by infusion.
• the antibiotics may be provided as pharmaceutically acceptable salts, such as nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as but not limited to hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as, but not limited to, acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, methansulfonic acid, glucuronic acid, malic acid, gluconic acid, lactic acid, aspartic acid, or malonic acid.
• inorganic acids such as but not limited to hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
• organic acids such as, but not limited to, acetic acid, maleic acid, tartaric acid, citric acid, succinic acid, methansulfonic acid, glucuronic acid, malic acid, gluconic acid, lactic acid, aspartic acid, or malonic acid.
• the formulation may be administered by injection, infusion, implantation (intravenous, intramuscular, subcutaneous, or the like) or by inhalation in dosage forms, formulations, or via suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers, solvents, diluents, and adjuvants.
• suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers, solvents, diluents, and adjuvants.
• Formulations for parenteral use may be provided in unit dosage forms (e.g., in single dose ampoules and vials), in vials containing several doses and in which a suitable preservative may be added (see below), in prefilled syringes, or in prefilled IV bags.
• compositions described herein may be in the form suitable for sterile injection.
• Formulations may include solutions containing rifabutin.
• Rifabutin solutions and methods of making rifabutin solutions are described in co-owned, co-pending U.S. Application No. 62/902,019, the contents of which are incorporated herein by reference.
• administration of the composition by IV administration may be favored over oral administration because it allows for rapid introduction of the antibiotic into systemic circulation, provides complete bioavailability, allows to better control the pharmacokinetic parameters that are driving the pharmacological efficacy, and avoids issues of stability in the gastrointestinal tract and absorption.
• the typical dosage of rifabutin is that able to reach plasma or local levels in which rifabutin Cmax is >2mg/L but ⁇ 50mg/L and AUC is 10 mg*h/L ⁇ 200 mg*h/L.
• Formulations may be formulated for parenteral administration, such as by injection or infusion.
• the injection or infusion may be subcutaneous or intravenous. Treating baumannii infections
• the combination therapies of the invention are useful for treating an A. baumannii infection in a subject.
• the subject may be a human.
• the subject may be a pediatric, a newborn, a neonate, an infant, a child, an adolescent, a pre-teen, a teenager, an adult, or an elderly subject.
• the subject may be in critical care, intensive care, neonatal intensive care, pediatric intensive care, coronary care, cardiothoracic care, surgical intensive care, medical intensive care, long term intensive care, an operating room, an ambulance, a field hospital, or an out-of-hospital field setting.
• the subject may have an A. baumannii infection that is resistant to an antibiotic.
• the A. baumannii infection may be resistant to one or more of an aminocyclitol, aminoglycoside, beta-lactam, beta-lactamase inhibitor, carbapenem, cephalosporin, polymyxin, quinolone, rifamycin, sulfonamide, tetracycline, amikacin, trimethoprim-sulfamethoxazole, cefepime, cefiderocol, ceftazidime, chloramphenicol, ciprofloxacin, colistin, doripenem, gentamicin, imipenem, levofloxacin, meropenem, penicillin, piperacillin, rifabutin, rifampicin, tazobactam, and tigecycline.
• the A. baumannii infection may be resistant to rifabutin, colistin,
• the antibiotics in the combination therapy may be administered simultaneously or sequentially.
• Sequential administration or alternating administration may include providing each antibiotic exclusively for a period of time.
• Sequential administration may include a period of overlap in which the subject is provided both the IV formulation containing rifabutin and the formulation containing the other therapeutic.
• the periods of exclusivity and periods of overlap may independently be 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week or 2 weeks.
• SoC standard of care
• MIC checkerboard minimum inhibitor concentration
• Rifabutin / colistin synergy was observed in 100% of the strains, the synergy was strong and independent of the initial resistance level towards rifabutin or colistin.
• the activity of rifabutin was superior to that of rifampicin when combined with colistin because the synergy with rifampicin was dependent of the initial resistance level towards rifampicin and the presence or absence of rpoB mutations as described in the literature.
• the rifabutin / colistin combination was active on strains resistant to rifabutin (including isolates with rpoB mutations) and/or to colistin, indicating that the combination overcomes both resistances.
• rifabutin has the ability to improve antibacterial activity of cefiderocol and colistin against A. baumannii strains.
• BV-015-3219-001-02 (rifabutin, (batch no. 17008MR89D)) was manufactured by Olon S.p.A. and 10 g/L stock solutions were prepared in DMSO. Stock solutions of rifampicin (Sigma R3501) and cefiderocol (Synnovator SYNNAAX397783) were prepared at 10 mg/mL in DMSO.
• the A. baumannii clinical isolates used in this study are from the BioVersys strain collection. The strains were stored at -80 °C as 20% (v/v) glycerol stock cultures.
• FICI Fractional Inhibitory Concentration Index
• synergy is defined when there is at least a 4-fold decrease in the MIC of the antibiotics tested in combination compared with the MIC of the antibiotics tested alone.
• FIG. 1 is an image of a 96-well plate checkerboard of A. baumannii cells cultured in various concentrations of rifabutin and colistin. The wells used to determine the MICs of the antibiotics alone are circled in green, the wells of the combination MICs are circled in blue, and the well used to calculate the FICI is circled in red.
• FIG. 2 is an image of a 96-well plate checkerboard of A.
• Rifabutin decreases MICs of cefiderocol of> 4 folds against the A. baumannii strains tested.
• cefiderocol in combination with rifabutin had little or no effect on activity of rifabutin towards isolates with mutations in the rpoB gene.
• rifabutin produced at least a 4-fold decrease in the MIC of cefiderocol against all the Acinetobacter baumannii strains tested.
• Rifabutin shows strong synergy with colistin on 100% of the A. baumannii strains tested.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Otolaryngology (AREA)
• Dermatology (AREA)
• Pulmonology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (11)

Applications Claiming Priority (8)

Publications (1)

Family

ID=72432957

Family Applications (2)

Family Applications After (1)

Country Status (17)

Families Citing this family (1)

Family Cites Families (15)

• 2020
  • 2020-08-03 PH PH1/2022/550610A patent/PH12022550610A1/en unknown
  • 2020-08-03 CN CN202080077930.0A patent/CN115052597B/zh active Active
  • 2020-08-03 JP JP2022516161A patent/JP7769605B2/ja active Active
  • 2020-08-03 US US16/983,718 patent/US11207305B2/en active Active
  • 2020-08-03 KR KR1020227012086A patent/KR20220103698A/ko active Pending
  • 2020-08-03 AU AU2020344214A patent/AU2020344214B2/en active Active
  • 2020-08-03 JP JP2022516163A patent/JP7804570B2/ja active Active
  • 2020-08-03 HR HRP20240818TT patent/HRP20240818T1/hr unknown
  • 2020-08-03 EP EP20768692.4A patent/EP4028001B1/en active Active
  • 2020-08-03 AU AU2020347536A patent/AU2020347536B2/en active Active
  • 2020-08-03 US US16/983,689 patent/US11351158B2/en active Active
  • 2020-08-03 CA CA3154317A patent/CA3154317A1/en active Pending
  • 2020-08-03 BR BR112022004672A patent/BR112022004672A2/pt unknown
  • 2020-08-03 PL PL20768692.4T patent/PL4028001T3/pl unknown
  • 2020-08-03 HU HUE20768692A patent/HUE066936T2/hu unknown
  • 2020-08-03 CN CN202511016208.7A patent/CN120860031A/zh active Pending
  • 2020-08-03 ES ES20768692T patent/ES2982067T3/es active Active
  • 2020-08-03 RS RS20240688A patent/RS65681B1/sr unknown
  • 2020-08-03 MX MX2022003077A patent/MX2022003077A/es unknown
  • 2020-08-03 CA CA3154129A patent/CA3154129A1/en active Pending
  • 2020-08-03 EP EP24169078.3A patent/EP4420673A3/en active Pending
  • 2020-08-03 WO PCT/IB2020/000645 patent/WO2021048610A1/en not_active Ceased
  • 2020-08-03 EP EP20768691.6A patent/EP4028000A1/en active Pending
  • 2020-08-03 CN CN202080077348.4A patent/CN114980889A/zh active Pending
  • 2020-08-03 BR BR112022004645A patent/BR112022004645A2/pt unknown
  • 2020-08-03 SM SM20240250T patent/SMT202400250T1/it unknown
  • 2020-08-03 WO PCT/IB2020/000647 patent/WO2021048611A1/en not_active Ceased
• 2021
  • 2021-12-27 US US17/562,496 patent/US11766425B2/en active Active
• 2022
  • 2022-06-06 US US17/833,326 patent/US11833139B2/en active Active
• 2023
  • 2023-10-20 US US18/491,243 patent/US12257241B2/en active Active
• 2025
  • 2025-03-24 US US19/088,662 patent/US20250281469A1/en active Pending
  • 2025-09-02 JP JP2025145104A patent/JP2025176113A/ja active Pending
  • 2025-10-31 JP JP2025184422A patent/JP2026016690A/ja active Pending

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events